Amyloidosis

Amyloidosis includes sporadic, familial, inherited, and infectious disease processes. In the supplied grounding, transthyretin amyloidosis can arise from misfolded transthyretin with either normal or variant genetic sequence, and some forms are associated with inherited variants. The grounding also supports inflammation-driven serum amyloid A production as a precursor context for amyloid-related disease.

The core mechanism is protein misfolding with formation of amyloid fibrils that deposit in tissues. These deposits accumulate in the extracellular space or within organs and progressively interfere with normal tissue architecture and function. The grounding also highlights the cross-β amyloid structure and, in cardiac amyloidosis, fibril deposition in the myocardium leading to cardiac dysfunction.

Inherited variants are a risk factor for some forms, particularly transthyretin amyloidosis. Aging is associated with transthyretin amyloidosis, and the literature also notes sex differences in transthyretin cardiac amyloidosis, with men more commonly affected. Inflammatory states are relevant to serum amyloid A induction, which is linked to amyloid-related disease processes.

Treatment is described at the level of disease-modifying approaches rather than specific regimens. The grounding supports therapies aimed at reducing amyloid formation, stabilizing the disease process, and, in newer approaches, promoting immune-mediated removal of amyloid fibrils. Multimodality imaging is used to support diagnosis, quantify amyloid burden, and monitor response to therapy.